Sjogren's Syndrome
2
Pipeline Programs
3
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
2100%
Competitive Landscape
2 companies ranked by most advanced pipeline stage
GS
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Gilead SciencesLanraplenib
Clinical Trials (1)
Total enrollment: 152 patients across 1 trials
Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome
Start: May 2017Est. completion: Oct 2019152 patients
Phase 2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space